文献速递神经免疫

基于风险-获益决策分析选择多发性硬化一线治疗

Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
PubMed 文献 · Neurology · 2017-01-13

研究采用Markov决策模型,评估那他珠单抗、芬戈莫德或醋酸格拉替雷治疗多发性硬化30年的残疾进展与进行性多灶性白质脑病风险,整合为质量调整生命年。结果显示那他珠单抗一线治疗净获益最高,且延迟残疾进展至EDSS≥6.0。

要点

  • 那他珠单抗一线治疗30年净获益15.06 QALYs,高于芬戈莫德和醋酸格拉替雷。
  • 那他珠单抗延迟EDSS≥6.0至22.7年,芬戈莫德17.0年,醋酸格拉替雷12.4年。
  • 那他珠单抗治疗早期死亡相对风险增高,随PML风险特征变化。

核心结论

  • 那他珠单抗作为一线治疗在PML风险、死亡和并发症全范围内净获益最高。

研究设计与样本

  • 研究构建Markov决策模型,模拟多发性硬化患者接受那他珠单抗、芬戈莫德或醋酸格拉替雷治疗30年。

主要发现

  • 那他珠单抗一线治疗30年净获益15.06 QALYs,芬戈莫德13.99 QALYs,醋酸格拉替雷12.71 QALYs。
  • 那他珠单抗延迟EDSS≥6.0至22.7年,芬戈莫德17.0年,醋酸格拉替雷12.4年。
  • 与未治疗患者相比,那他珠单抗治疗早期死亡相对风险增高,且随PML风险特征变化。

临床怎么用

  • 整合长期治疗风险与获益的模型可支持分层临床决策和患者咨询。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To integrate long-term measures of disease-modifying drug efficacy and risk to guide selection of first-line treatment of multiple sclerosis. METHODS: We created a Markov decision model to evaluate disability worsening and progressive multifocal leukoencephalopathy (PML) risk in patients receiving natalizumab (NTZ), fingolimod (FGL), or glatiramer acetate (GA) over 30 years. Leveraging publicly available data, we integrated treatment utility, disability worsening, and risk of PML into quality-adjusted life-years (QALYs). We performed sensitivity analyses varying PML risk, mortality and morbidity, and relative risk of disease worsening across clinically relevant ranges. RESULTS: Over the entire reported range of NTZ-associated PML risk, NTZ as first-line therapy is predicted to provide a greater net benefit (15.06 QALYs) than FGL (13.99 QALYs) or GA (12.71 QALYs) treatment over 30 years, after accounting for loss of QALYs due to PML or death (resulting from all causes). NTZ treatment is associated with delayed worsening to an Expanded Disability Status Scale score ≥6.0 vs FGL or GA (22.7, 17.0, and 12.4 years, respectively). Compared to untreated patients, NTZ-treated patients have a greater relative risk of death in the early years of treatment that varies according to PML risk profile. CONCLUSIONS: NTZ as a first-line treatment is associated with the highest net benefit across full ranges of PML risk, mortality, and morbidity compared to FGL or GA. Integrated modeling of long-term treatment risks and benefits informs stratified clinical decision-making and can support patient counseling on selection of first-line treatment options.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bargiela D, Bianchi MT, Westover MB, et al. Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology. 2017. PMID: 28087821. doi:10.1212/WNL.0000000000003612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。